BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BL-M09D1 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BL-M09D1\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06954077-2399@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:BL-M09D1: Phase 1 readout est. (NCT06954077)
DESCRIPTION:BL-M09D1\, phase 1.\nStudy: A Study of BL-M09D1 in Patients Wit
 h Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid T
 umors\nEstimated primary completion: May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/bl-m09d1#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06954077
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056556-2399@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BL-M09D1: Phase 1 readout est. (NCT07056556)
DESCRIPTION:BL-M09D1\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer and Other Solid Tumors\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bl-m09d1#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070565
 56
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769229-2399@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BL-M09D1: Phase 2 readout est. (NCT07769229)
DESCRIPTION:BL-M09D1\, phase 2.\nStudy: A Study of BL-M09D1 in Patients Wit
 h Locally Advanced or Metastatic Gynecological Malignancies and Other Soli
 d Tumors\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bl-m09d1#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07769229
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837622-2399@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BL-M09D1: Phase 2 readout est. (NCT07837622)
DESCRIPTION:BL-M09D1\, phase 2.\nStudy: A Study of BL-M09D1 in Patients Wit
 h Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumo
 rs\nEstimated primary completion: December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bl-m09d1#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07837622
URL:https://assetmemo.bio/drug/bl-m09d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
